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Background
We reported previously the construction, in vitro charac-
terization and preliminary immunogenicity studies of a
novel recombinant 17D yellow fever vaccine expressing
HIV-1 p24 (17Dp24). Here we further evaluated 17Dp24-
induced Ag-specific cell-mediated immune responses as
well as compared this p24-specific immune reactions to
those of other viral vectors (MVA and Ad) carrying the
same HIV-1 antigen with the goal to compare the quantity
and quality of the different immune responses.
Methods
The Ag-specific polyfunctional T cell response was meas-
ured by multi-parameter intracellular cytokine staining
(ICS) and cytokine release was measured by cytokine
beads array(CBA). The quality of 17Dp24 induced cell-
mediated immunity was further investigated with a
mouse challenge model using a recombinant vaccinia
virus expressing HIV-Gag (including p24).
Results
Mouse immunogenicity experiments indicated that the
17Dp24 vaccine candidates were able to induce a robust
CD8+ and CD4+ T-cell response. Upon Ag stimulation in
vitro, INFγ, IL-2 as well as the expression of both cytokines
were observed in up to 1.5% of both T-cell populations.
Although a 1,5-fold greater INFγ CD8+ T-cell response is
generated for MVA and Ad5 when comparing the immune
responses with those of our 17D recombinants, two to
threefold more polyfunctional CD4+ and CD8+ T-cells,
expressing both INFγ and IL-2, was noticed for the recom-
binant 17D viruses. Furthermore in contrast to the other
vectors 17D recombinants were also able to generate IL-4
and IL-5 producing Ag-specific CD4+ T-cells. Lastly, viral
titers were reduced 100-fold when mice previously immu-
nized with the 17Dp24 vaccine candidate were challenged
with the vaccinia-Gag virus, indicating a functional
17Dp24 induced cell-mediated immune response.
Conclusion
These studies confirmed that the 17D yellow fever virus
vaccine strain could be pursued as alternative viral vector
for HIV vaccine development.
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